Menu
← Oncology Approval Tracker
FDA DECISION ·
Rybrevant + carboplatin + pemetrexed
amivantamab-vmjw with carboplatin and pemetrexed · Janssen Biotech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment of locally advanced or metastatic non-small cell lung cancer with an FDA test-confirmed EGFR exon 20 insertion, using amivantamab with carboplatin and pemetrexed.
LAMPGEN ANALYSIS
Why it matters
The PAPILLON-based approval brought the antibody into first-line treatment for EGFR exon 20 insertion disease.
What research teams should watch
Make exon 20 insertion testing explicit and prepare for the initial infusion schedule and reaction monitoring.
PRIMARY RECORDS